1192u90 has been researched along with apomorphine in 3 studies
| Studies (1192u90) | Trials (1192u90) | Recent Studies (post-2010) (1192u90) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 9,205 | 287 | 780 |
| Protein | Taxonomy | 1192u90 (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hall, WR; Navas, F; Norman, MH; Rigdon, GC | 1 |
| Cooper, BR; Cox, RF; Durcan, MJ; Gengo, PJ; Jones-Humble, SA; Lyerly, D; Morgan, PF; Norton, RM; Russell, AV; Tang, FL; Wang, CM; Watson, MJ | 1 |
| Navas, F; Norman, MH; Rigdon, GC; Thompson, JB | 1 |
3 other study(ies) available for 1192u90 and apomorphine
| Article | Year |
|---|---|
Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Mice; Molecular Structure; Motor Activity; Piperazines; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship; Thiazoles | 1996 |
Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Biogenic Amines; Brain; Clozapine; Male; Neurons; Piperazines; Radioligand Assay; Rats; Thiazoles | 1996 |
Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzamides; Clozapine; Heterocyclic Compounds; Magnetic Resonance Spectroscopy; Mice; Molecular Structure; Piperazines; Raclopride; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Salicylamides; Thiazoles | 1996 |